| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0264-410X(98)00239-4 |
| P698 | PubMed publication ID | 10075167 |
| P2093 | author name string | Bhamarapravati N | |
| Yoksan S | |||
| Khin MM | |||
| Jirakanjanakit N | |||
| P2860 | cites work | Togavirus interference in Culex annulirostris mosquitoes | Q33390987 |
| A case of natural concurrent human infection with two dengue viruses. | Q40821135 | ||
| Evaluation of Toxorhynchites Splendens (Diptera: Culicidae) as a Bioassay Host for Dengue Viruses1 | Q40846830 | ||
| Quantitative aspects of replication of dengue viruses in Aedes albopictus (Diptera: Culicidae) after oral and parenteral infection | Q40884608 | ||
| The use of mosquitoes to detect and propagate dengue viruses | Q40901556 | ||
| Dual infections of Aedes aegypti with arboviruses. I. Arboviruses that have no apparent cytopathic effect in the mosquito. | Q40946190 | ||
| Study of bivalent dengue vaccine in volunteers | Q42989607 | ||
| Interference between bunyaviruses in Aedes triseriatus mosquitoes | Q43031391 | ||
| Formation of reassortant bunyaviruses in dually infected mosquitoes | Q43034247 | ||
| Dual infections of eastern and western equine encephalitis viruses in Culex tarsalis | Q43707888 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Dengue virus | Q476209 |
| attenuated vaccine | Q1810913 | ||
| Toxorhynchites splendens | Q13853563 | ||
| P304 | page(s) | 597-601 | |
| P577 | publication date | 1999-02-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | The use of Toxorhynchites splendens for identification and quantitation of serotypes contained in the tetravalent live attenuated dengue vaccine | |
| P478 | volume | 17 |
| Q51336430 | Complete Genome Sequence of a Zika Virus Strain Isolated from the Serum of an Infected Patient in Thailand in 2006. |
| Q34759091 | Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). |
| Q47403621 | Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial |
Search more.